NRIX
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) has 8 SEC Form 4 filings (22 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 2, 2026.
The most active filer is Chief Legal Officer Ring Christine with 4 filings. Insiders have net sold $1.4M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Arthur T. Sands
- Employees:314
- HQ:Brisbane, CA, US
- IPO:2020-07-24
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.4M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$2.4B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Legal Officer | Sale | 11,008 | $259K | Jul 2 | SEC ↗ | |
| Chief Scientific Officer | Sale | 5,394 | $108K | Jun 25 | SEC ↗ | |
| Chief Legal Officer | Sale | 28,935 | $581K | Jun 25 | SEC ↗ | |
| Chief Financial Officer | Sale | 14,055 | $233K | May 5 | SEC ↗ | |
| Chief Legal Officer | Sale | 5,394 | $90K | May 1 | SEC ↗ | |
van Houte HansFirst filing | Chief Financial Officer | Sale | 2,388 | $40K | Apr 30 | SEC ↗ |
Ring ChristineFirst filing | Chief Legal Officer | Sale | 3,214 | $53K | Apr 30 | SEC ↗ |
Hansen GwennFirst filing | Chief Scientific Officer | Sale | 3,214 | $53K | Apr 30 | SEC ↗ |
Related companies
Nurix Therapeutics, Inc. is in the Healthcare sector.